Clinical Trial Update: A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on MRG002 in patients with HER2-positive advanced solid tumors and locally advanced or metastatic gastric/GEJ cancer, spanning Phase 1 and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• MRG002

Snippet

Sponsor: Shanghai Miracogen Inc. | Conditions: Advanced Solid Tumors, Advanced or Metastatic Gastric Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING